Investments in medical technology remain strong despite weakened economy
WASHINGTON Private investment in the United States medical technology industry has remained strong over the last year and a half despite the credit crunch, according to a report released recently by research firm Ernst & Young.
Meanwhile, the 301 publicly traded medical technology companies with headquarters in the U.S. have produced solid growth in revenues and earnings, driven by continued demand and innovation due to medical and demographic trends, according to the report, titled “Pulse of the Industry: US Medical Technology Report 2008.”
“White the credit crunch has depressed equity financing, venture capital and deal activity remain solid,” Ernst & Young U.S. medical technology leader Richard Ramko said. “The industry is poised for growth in the years ahead due to aging populations, the wider prevalence of chronic diseases and an expected surge in demand for companion diagnostics to accompany new generations of targeted therapies.”
Zebra to provide industry printer services to Managed Healthcare Associates
VERNON HILLS, Pa. A company that provides printing services for the healthcare industry and the country’s largest alternate-site GPO have signed a three-year agreement to provide barcode and card printers.
Zebra Technologies will provide Managed Healthcare Associates with its printers, as well as supplies and service agreements, at almost 500 of MHA’s member facilities for identification, tracking and access-control applications.
“Increasing patient safety is among the highest priorities in healthcare today,” MHA contract coordinator Kelly Decker said. “Having effective information technology in place is a key step in building a culture of safety that enables providers to improve outcomes and quality of care throughout their organizations.”
According to the Institute of Medicine, at least 1.5 million preventable adverse drug events happen every year in the United States, thought bar coding has been shown to reduce dangerous and expensive medical errors.
Drug adherence study shows that patients suffering despression often go off medication
NEW YORK A company that provides patient adherence and education programs released a study recently that examined adherence rates among patients on SSRI/SNRI antidepressant therapy.
The study, by Burlington, Mass.-based Adheris, found that patients new to antidepressant treatment and those who had restarted therapy after a lapse of six months or more were twice as likely to discontinue therapy in the first 30 days of treatment versus patients previously dispensed an antidepressant.
It also found that the greatest differences in the duration of antidepressant use were not among patients using different drugs, but among patients taking the same drug with different levels of prior experience with antidepressants.
The study appears in the September issue of the journal Clinical Therapeutics. It included more than 211,000 patients taking SSRI/SNRIs from 1,157 retail pharmacies across the country.